Glaukos Receivables 2014-2024 | GKOS

Glaukos receivables for the quarter ending June 30, 2024 were $0.051B, a 30.48% increase year-over-year.

  • Glaukos receivables for 2023 were $0.04B, a 10.47% increase from 2022.
  • Glaukos receivables for 2022 were $0.036B, a 7.88% increase from 2021.
  • Glaukos receivables for 2021 were $0.033B, a 7.27% decline from 2020.

Glaukos Receivables 2014-2024 | GKOS

  • Glaukos receivables for 2023 were $0.04B, a 10.47% increase from 2022.
  • Glaukos receivables for 2022 were $0.036B, a 7.88% increase from 2021.
  • Glaukos receivables for 2021 were $0.033B, a 7.27% decline from 2020.
Related Stocks
Company NameMarket
Cap
Thermo Fisher Scientific (TMO)$211B
Intuitive Surgical (ISRG)$191.1B
Alcon (ALC)$45.7B
IQVIA Holdings (IQV)$39.8B
Edwards Lifesciences (EW)$39.1B
IDEXX Laboratories (IDXX)$35.5B
DexCom (DXCM)$27.3B
Waters (WAT)$22.8B
SONOVA HOLDING (SONVY)$22.1B
STERIS (STE)$21.6B
Hologic (HOLX)$18.3B
Sysmex ADR (SSMXY)$12.9B
Fresenius Medical Care AG KGaA (FMS)$12.5B
Globus Medical (GMED)$11B
Teleflex (TFX)$9.1B
Penumbra (PEN)$9.1B
Masimo (MASI)$8.7B
PROCEPT BioRobotics (PRCT)$5.2B
Integer Holdings (ITGR)$4.6B
Inari Medical (NARI)$3B
TransMedics (TMDX)$2.9B
LivaNova (LIVN)$2.8B
Veracyte (VCYT)$2.8B
Nihon Kohden (NHNKY)$2.6B
Elekta AB (EKTAY)$2.3B
Tandem Diabetes Care (TNDM)$2B
Integra LifeSciences Holdings (IART)$1.9B
RxSight (RXST)$1.8B
Alphatec Holdings (ATEC)$1.3B
Pulse Biosciences (PLSE)$1.2B